The Center Faculty come from all four UCSF Schools and conduct research and teaching in every aspect of tobacco control, from efforts by the tobacco industry to manipulate international politics to the molecular biology of nicotine addiction.

Steve Schroeder, MD


Determinants of medical expenditures, efficacy of medical cost containment, quality of care, and tobacco control with an emphasis on smoking cessation.

Mark Schumacher, MD, PhD


My goal is to leverage a better understanding of peripheral pain transduction to inspire more effective and non-addictive treatments for pain. In collaboration with the Hellman laboratory, we are investigating the role of TRPV1 and CB1 in sensory neurons as anti-inflammatory and analgesic targets for the minor cannabinoids.

Joel Simon, MD, MPH

Professor Emeritus

Hospital-based and out-patient clinical trials of smoking cessation.

Elizabeth Smith, PhD

Social Behavioral Sciences

"Legitimate" tobacco industry activities, and tobacco industry relationships with other groups.

Joanne Spetz, PhD

Institute for Health Policy Studies

Economics of the health care workforce, shortages and supply of registered nurses, organization and quality of the hospital industry, impact of health information technology, effect of medical marijuana policy on youth substance use, and the substance use disorder treatment workforce.

Matt Springer, PhD


Mechanisms underlying vascular reactivity and how they are affected by exposure to secondhand smoke from tobacco and marijuana.

Gideon St Helen, PhD

Assistant Professor

Utility and evaluation of biological markers (biomarkers) of tobacco use and exposure for epidemiology, risk assessment, product regulation, and identification of susceptibility factors.

Hai-Yen Sung, PhD

Institute for Health & Aging

Costs of smoking, costs of illness, evaluation of the economic impact of tobacco taxation and other tobacco control policies, secondhand smoke exposure, and cancer screening and outcomes.

Janice Tsoh, PhD


Smoking cessation treatment in vulnerable populations including Asian Americans, and clients in substance abuse treatment with focus on use of social network and digital health technology to promote utilization of and delivering evidence-based treatment in underserved populations.  

Candy Tsourounis, PharmD

Clinical Pharmacy